Supporting the fight against cancer
Cancer incidence is expected to reach 30.2 million in 2040 and account for 16.3 million deaths that year.1
At SOPHiA GENETICS, our goal is to turn cancer from a potentially lethal condition to chronic disease by providing healthcare professionals with data-driven insights.
Using data-driven medicine, healthcare professionals supplement their own experience and intuition with data insights and shared knowledge from their peers to inform their action.
1International Agency for Research on Cancer. (2020) 'Cancer Tomorrow', World Health Organization [Online]. Available at: https://gco.iarc.fr/tomorrow/en (Accessed: 22 April 2021)
A unique multimodal approach to tackle cancer
A growing understanding of genomics has dramatically advanced cancer diagnosis and treatment. However, genomics is only one piece of the biological equation.
We believe that phenotypic information is needed to put genomic information into context and provide a more complete picture of biology and disease.
The SOPHiA DDM™ platform can compute different digital health data modalities separately or together and combine genomic and phenotypic data to deliver insightful information to further advance global understanding of cancer.
We have developed proprietary capabilities in AI- and machine learning-enabled exploration of such multimodal signatures. Through these, we unlock the synergistic power of next-generation health data to break new ground in predictive capabilities.
Solid tumors account for more than 90% of new cancer cases worldwide. That’s more than 30 new cases diagnosed every minute.
Butcher, L. (2008) ‘Solid tumors: Prevalence, economics, and implications for payers and purchasers’, Biotechnology Healthcare, 5(1), pp20-21.
From targeted to comprehensive profiling, SOPHiA GENETICS supports healthcare professionals in their journey to analyze each solid tumor.
More than 900,000 people worldwide are diagnosed with blood cancer every year.
World Cancer Research Fund International. ‘Worldwide cancer data: Global cancer statistics for the most common cancers’ [Online]. Available at: http://www.wcrf.org/int/cancer-facts-figures/worldwide-data (Accessed: 22 April 2021)
As science and guidelines for myeloid malignancies constantly evolve, so does SOPHiA GENETICS, with the ability to support professionals to confidently access the data they need.
Hereditary causes account for approximately 10% of all cancers.
Al Harthi, F. S., et al. (2020) ‘Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population’, npj Genomic Medicine, 5, 3.
SOPHiA GENETICS supports the rapid detection of known hereditary cancer genes to inform efficient decision-making all along the cancer care journey.
SOPHiA GENETICS supports every stage of the care path*
Assist cancer prevention
Support cancer evaluation methods to help lower cancer incidence
Facilitate early detection and diagnosis of cancer to continuously help improve patient care
Inform treatment decisions
Identify novel gene biomarkers and aid prediction of individual treatment response to available therapies*
Enable tumor monitoring
Benefit from the precision of tumor characteristics and insights generated through multimodal data
Our multimodal approach to oncology
Covers the entire care path
Generates insights from a complex multimodal dataset
- COLLABORATIVE INTELLIGENCE
Allows experts to share knowledge in real time
Reaches high analytical performance*
Offers a scalable, decentralized model